Quick answers

What is CJC-1295 DAC and what is it used for in research?
CJC-1295 DAC is classified within the GH Secretagogue group. Modified GHRH(1-29) with a maleimidopropionic-acid linker that covalently binds endogenous albumin, extending half-life from minutes to days. Drives sustained, non-pulsatile GH and IGF-1 elevation — distinct from the No-DAC daily-dosing variant. Research applications focus on the pathways outlined below. All references on this page describe published research only, CJC-1295 DAC is supplied for in-vitro and laboratory use, not for human consumption.
How does CJC-1295 DAC work?
Primary mechanism: CJC-1295 with Drug Affinity Complex; albumin-bound long-acting GHRH analog extending half-life from ~7 min to ~7 days. Downstream effects depend on dose, timing, and the biological system under investigation. Receptor binding and post-receptor signalling for CJC-1295 DAC remain areas of active study, and several proposed effects are supported only by preclinical data.
What is the typical CJC-1295 DAC research dose?
Published research protocols for CJC-1295 DAC describe per-dose ranges of 1–2 mg / week, with a weekly total near 1–2 mg, administered weekly sc. Typical cycle: 12 weeks on / 4 off. These ranges reflect the literature and are not dosing recommendations for any individual.
Where can I buy CJC-1295 DAC in Thailand?
CJC-1295 DAC is supplied by Thailand Peptides, a Bangkok-based research-peptide supplier. Orders are placed directly via WhatsApp to the Bangkok research desk, no cart, no account, no forms. Pricing and shipping are provided on request. Open a line with the research desk →
How fast can CJC-1295 DAC be delivered in Thailand?
Same-week delivery across Thailand is standard for orders confirmed within business hours (GMT+7, Monday–Saturday). Bangkok metro deliveries typically arrive within 1–3 business days; other provinces within 3–5. Regional Southeast Asia shipping is available on request.

What is CJC-1295 DAC?

CJC-1295 DAC is a research peptide in the GH Secretagogue class. CJC-1295 with Drug Affinity Complex; albumin-bound long-acting GHRH analog extending half-life from ~7 min to ~7 days. It is studied at per-dose ranges of 1–2 mg / week (1–2 mg weekly), administered weekly sc over cycles of 12 weeks on / 4 off. Supplied in Thailand by Thailand Peptides, Bangkok-based, research use only.

Modified GHRH(1-29) with a maleimidopropionic-acid linker that covalently binds endogenous albumin, extending half-life from minutes to days. Drives sustained, non-pulsatile GH and IGF-1 elevation — distinct from the No-DAC daily-dosing variant.

Published and preclinical data are summarised below; dose ranges shown reflect protocols in the research literature and should be interpreted accordingly.

How does CJC-1295 DAC work?

Primary mechanism: CJC-1295 with Drug Affinity Complex; albumin-bound long-acting GHRH analog extending half-life from ~7 min to ~7 days. Research on CJC-1295 DAC implicates downstream effects on related signalling cascades, with magnitude and clinical relevance dependent on dose, timing, and individual pharmacogenomic factors.

Receptor binding affinity and post-receptor signalling for CJC-1295 DAC remain areas of active investigation; several proposed effects within the GH Secretagogue class are currently supported only by in-vitro or rodent data, and should be interpreted accordingly.

CJC-1295 DAC dosage & protocol

Reference protocol for CJC-1295 DAC (research context only, drawn from published literature):

  • Per dose: 1–2 mg / week
  • Weekly total: 1–2 mg
  • Frequency: Weekly SC
  • Cycle: 12 weeks on / 4 off
Order CJC-1295 DAC
Ready to order? WhatsApp the Bangkok research desk, pricing and availability confirmed within the chat.
Ask about CJC-1295 DAC ≥98% HPLC purity · supplier COA on file · Bangkok-based

Stacking CJC-1295 DAC

Commonly referenced pairing with CJC-1295 DAC: Ipamorelin (GHRP); also see /peptides/cjc-1295 (No DAC variant). Stacking rationale should be grounded in complementary mechanisms, not additive speculation; interactions at shared receptors or enzymatic pathways should be accounted for. Both compounds in a CJC-1295 DAC stack are supplied by Thailand Peptides on the same order via the Bangkok research desk.

Contraindications

Active malignancy, pregnancy. Additional caution is warranted in individuals with hepatic or renal impairment, endocrine disorders, or concurrent pharmacotherapy affecting the pathways described above.

Compare CJC-1295 DAC with: CJC-1295

Citations

  1. Teichman SL, et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295. J Clin Endocrinol Metab. 2006. PMID: 16352683
  2. Ionescu M, et al. Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295, a long-acting GHRH analog. J Clin Endocrinol Metab. 2006. PMID: 17018654

References curated from PubMed. Additional literature summarised in the Thailand Peptides research library.